Emicizumab biosimilar (Jushi Biopharmaceutical)

艾美赛珠单抗生物类似药(巨石生物制药)

Report date: 2026/03/06 20:02:51

Base Information

Drug NameEmicizumab biosimilar (Jushi Biopharmaceutical)
Drug Alias NameSYS6053SYS-6053
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunoglobulin G inhibitors
TargetsImmunoglobulin G
Therapy Area/IndicationsHemorrhageHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJushi Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJushi Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHemorrhageHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A